Dr. Reddy’s Teraleve ® 4mg and 8mg Fesoterodine Fumarate Prolonged-Release tablets have been available in the UK since their launch on 1st June 2022.
Therapeutic indications:
- Indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.
Presentation:
4mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number ‘4’.
8mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number ‘8’.
Tablets are packaged in aluminium-aluminium blisters in a carton with a PIL.
| Product Name | Strength | Pack Size | PIP Code | EAN No. | Legal Category |
| Teraleve® Fesoterodine Fumarate Prolonged-Release Tablets | 4mg | 28 | 125-6924 | 5036072008328 | POM |
| Teraleve® Fesoterodine Fumarate Prolonged-Release Tablets | 8mg | 28 | 125-6932 | 5036072008311 | POM |
Teraleve® Fesoterodine Fumarate Prolonged-Release tablets are available from your local wholesaler or by contacting Dr.Reddy’s on 01223 651475 or [email protected].
Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: http://www.medicines.org.uk. Prescribers are recommended to consult the summary of product characteristics before prescribing – SmPC.
